AstraZeneca Details Deep R&D Cuts | March 8, 2010 Issue - Vol. 88 Issue 10 | Chemical & Engineering News
Volume 88 Issue 10 | p. 19 | Concentrates
Issue Date: March 8, 2010

AstraZeneca Details Deep R&D Cuts

Department: Business | Collection: Economy
Keywords: pharmaceuticals, R&D, layoffs

Following a January announcement of plans for deep R&D cuts, AstraZeneca has revealed which facilities and therapeutic areas will be affected. The company is ending discovery research in thrombosis, acid reflux, ovarian and bladder cancers, systemic scleroderma, schizophrenia, bipolar disorder, depression and anxiety, hepatitis C, and vaccines other than respiratory syncytial virus and influenza. In the U.K., Astra­Zeneca plans to close its Leices­ter­shire and Cambridge sites, affecting roughly 1,000 researchers, and end pharmaceutical development work at the Avlon facility near Bristol. AstraZeneca will close its Lund, Sweden, site. It will also end discovery research in Wilmington, Del., affecting some 550 scientists.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment